# Commentary on the “A multidisciplinary opioid-reduction pathway for robotic prostatectomy: outcomes at year one”

**Authors:** Binbin Zhu, Angyang Cao, Yijun Chen

PMC · DOI: 10.1186/s13741-024-00392-w · 2024-07-11

## TL;DR

This commentary reviews a study on reducing opioid use after robotic prostatectomy, highlighting its promising results but also significant limitations.

## Contribution

The commentary identifies limitations in the study's design and emphasizes the need for further rigorous research on opioid reduction pathways.

## Key findings

- The study observed reduced opioid consumption and shorter hospital stays after implementing the pathway.
- However, the pre-post design limits causal conclusions and key confounders were not fully addressed.
- The clinical significance of the observed changes remains uncertain.

## Abstract

Opioid-sparing multimodal analgesia is increasingly emphasized for postoperative pain management. This commentary discusses a study by Manning et al. on an opioid reduction pathway for robotic prostatectomy.

We reviewed the Manning et al. study, which implemented a multidisciplinary opioid reduction pathway and compared outcomes before and after pathway implementation. Outcomes included opioid use, pain scores, antiemetic use, length of stay, and readmissions.

The study found reduced opioid consumption, lower antiemetic use, shorter length of stay, and similar pain scores after pathway implementation. However, the pre-post-study design has limitations in attributing causality to the pathway itself. Key confounders were not fully accounted for. The clinical significance of the small reduction in length of stay is also questionable.

This commentary highlights important limitations of the Manning et al. study, including the retrospective design, potential confounding factors, small effect size, and lack of long-term outcomes. While the study provides early evidence for a multidisciplinary opioid reduction approach, further rigorous prospective research is needed to confirm the observed benefits and long-term impacts. Additional focus on direct opioid consumption, equivalent analgesia assessment, and clinically meaningful outcomes is warranted.

## Full-text entities

- **Diseases:** postoperative pain (MESH:D010149), pain (MESH:D010146)

---
Source: https://tomesphere.com/paper/PMC11241976